Saturday, May 30

**Session Title:** Developmental Therapeutics—Immunotherapy  
**Session Type:** Poster Session  
**Date:** Sat, May 30  
**Location:** S Hall A  
**Time:** 8:00 AM - 11:30 AM

- **Poster Board: #341**  
  Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A. (Abstract #3015)  
  *Scott N. Gettinger, MD*

---

**Session Title:** Breast Cancer—HER2/ER  
**Session Type:** Poster Session  
**Date:** Sat, May 30  
**Location:** S Hall A  
**Time:** 8:00 AM - 11:30 AM

- **Poster Board: #74**  
  Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC). (Abstract #585)  
  *Christian Jackisch, MD*
Session Title: Melanoma/Skin Cancers
Session Type: Oral Abstract Session
Date: Sat, May 30
Location: E354b
Time: 1:15 PM - 4:15 PM
Chair and/or Co-Chairs: Axel Hauschild, MD, and Sekwon Jang, MD

- 3:15 PM - 3:27 PM
  Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. (Abstract #9006)
  James M. G. Larkin, MD, PhD

Session Title: Health Services Research and Quality of Care
Session Type: Oral Abstract Session
Date: Sat, May 30
Location: S102
Time: 1:15 PM - 4:15 PM
Chair and/or Co-Chairs: Helen M. Parsons, PhD, MPH, and Ann H. Partridge, MD, MPH

- 2:27 PM - 2:39 PM
  Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405. (Abstract #6504)
  Deborah Schrag, MD, MPH

Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Session Type: Oral Abstract Session
Date: Sat, May 30
Location: E Hall D1
Time: 3:00 PM - 6:00 PM
Chair and/or Co-Chairs: Scott N. Gettinger, MD, and Charles M. Rudin, MD, PhD

- 3:00 PM - 3:12 PM
  Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial. (Abstract #7500)
  Gerard Zalcman, MD, PhD
Sunday, May 31

Session Title: Lung Cancer—Non-Small Cell Metastatic
Session Type: Oral Abstract Session
Date: Sun, May 31
Location: N Hall B1
Time: 8:00 AM - 11:00 AM
Chair and/or Co-Chairs: Luis G. Paz-Ares, MD, PhD, and Nithya Ramnath, MD

- **10:24 AM - 10:36 AM**
  Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673). (Abstract #8008)
  
  *Sai-Hong Ignatius Ou*

Session Title: Lymphoma and Plasma Cell Disorders
Session Type: Poster Session
Date: Sun, May 31
Location: S Hall A
Time: 8:00 AM - 11:30 AM

- **Poster Board: #352**
  Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin’s Lymphoma (NHL). (Abstract #8535)
  
  *Sven De Vos, MD, PhD*

- **Poster Board: #394**
  Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM). (Abstract #8576)
  
  *Shaji Kumar, MD*

- **Poster Board: #398**
  Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
  (Abstract #8580)
  
  *Cyrille Touzeau, MD*

Session Title: Plenary Session Including the Science of Oncology Award and Lecture
Session Type: Plenary Session
Date: Sun, May 31
Location: N Hall B1
Time: 1:00 PM - 4:00 PM
Chair and/or Co-Chairs: Peter P. Yu, MD, FACP, FASCO, and Alan P. Venook, MD
Session Title: Immunotherapy in Lung Cancer: A Paradigm Shift
Session Type: Clinical Science Symposium
Date: Sun, May 31
Location: E Hall D1
Time: 4:30 PM - 6:00 PM
Chair and/or Co-Chairs: Nathan A. Pennell, MD, PhD, and Geoffrey R. Oxnard, MD

- 4:42 PM - 4:54 PM
  Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). (Abstract #8010)
  Alexander I. Spira, MD, PhD

Monday, June 1

Session Title: Breast Cancer—HER2/ER
Session Type: Oral Abstract Session
Date: Mon, Jun 1
Location: N Hall B1
Time: 8:00 AM - 11:00 AM
Chair and/or Co-Chairs: Priya Rastogi, MD, and Tufia C. Haddad, MD

- 8:12 AM - 8:24 AM
  Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). (Abstract #501)
  Maura N. Dickler, MD

- 9:48 AM - 10:00 AM
  Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P). (Abstract #505)
  Luca Gianni, MD

- 10:00 AM - 10:12 AM
  Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.
  (Abstract #506)
  Nadia Harbeck, MD, PhD

- 10:12 AM - 10:24 AM
  Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. (Abstract #507)
  Paul Anthony Ellis
**Session Title:** Gynecologic Cancer  
**Session Type:** Oral Abstract Session  
**Date:** Mon, Jun 1  
**Location:** E354b  
**Time:** 8:00 AM - 11:00 AM  
**Chair and/or Co-Chairs:** Rebecca S. Kristeleit, MD, PhD, and John K. Chan, MD

- **9:12 AM - 9:24 AM**  
  Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial. (Abstract #5504)  
  Christian Kurzeder, MD

**Session Title:** Lung Cancer—Non-Small Cell Metastatic  
**Session Type:** Poster Session  
**Date:** Mon, Jun 1  
**Location:** S Hall A  
**Time:** 8:00 AM - 11:30 AM

- **Poster Board: #341**  
  A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). (Abstract #8019)  
  Leena Gandhi, MD, PhD

- **Poster Board: #350**  
  Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC). (Abstract #8028)  
  David R. Spigel, MD

- **Poster Board: #351**  
  Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. (Abstract #8029)  
  Leora Horn, MD, MSc

- **Poster Board: #352**  
  Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). (Abstract #8030)  
  Stephen V. Liu, MD
**Lymphoma**

**Session Title:** Lymphoma
**Session Type:** Oral Abstract Session
**Date:** Mon, Jun 1
**Location:** E450
**Time:** 9:45 AM - 12:45 PM
**Chair and/or Co-Chairs:** Owen A. O'Connor, MD, PhD, and Grzegorz S. Nowakowski, MD

- **10:09 AM - 10:21 AM**
  GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. (Abstract #LBA8502)
  
  *Laurie Helen Sehn, MDCM, MPH*

**Genitourinary (Nonprostate) Cancer**

**Session Title:** Genitourinary (Nonprostate) Cancer
**Session Type:** Oral Abstract Session
**Date:** Mon, Jun 1
**Location:** E Arie Crown Theater
**Time:** 9:45 AM - 12:45 PM
**Chair and/or Co-Chairs:** Guru Sonpavde, MD, and Ana M. Molina, MD

- **9:57 AM - 10:09 AM**
  A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). (Abstract #4501)
  
  *Daniel Peter Petrylak, MD*

**Melanoma/Skin Cancers**

**Session Title:** Melanoma/Skin Cancers
**Session Type:** Poster Session
**Date:** Mon, Jun 1
**Location:** S Hall A
**Time:** 1:15 PM - 4:45 PM

- **Poster Board: #263**
  Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. (Abstract #9020)
  
  *Anna C. Pavlick, DO*

- **Poster Board: #267**
  Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study. (Abstract #9024) Reinhard Dummer, MD